MMEDPMedpace Holdings, Inc.

Medpace runs clinical trials for small biotech companies — end to end, with its own people.

What distinguishes it from large contractors is that the company does not assemble a project from subcontractors but runs it with one team: medical oversight, laboratories, statistics and regulatory dossier preparation in house. For a small developer that matters more than price — it has no specialists of its own, and one mistake costs it the whole programme.

The backlog says more about the future than current revenue does, and the client base makes results sensitive to the availability of venture capital: when money gets dearer, start-ups pause programmes. Risks: biotech funding, cancelled studies and a shortage of research sites. The company pays no dividend but buys back stock actively.